Medicine and Dentistry
Child
100%
Patient
96%
Oncology
82%
Pediatrics
43%
Solid Malignant Neoplasm
37%
Combination Therapy
32%
Rhabdomyosarcoma
29%
Toxicity
26%
Development
23%
Neoplasm
21%
Therapeutic Procedure
20%
Adolescent
19%
Young Adult
19%
Disease
17%
Malignant Neoplasm
16%
Inpatient
16%
Ganglioneuroblastoma
15%
Osteosarcoma
15%
Chemotherapy
15%
Phase I Trials
13%
Childhood Cancer
13%
Pediatrics Patient
12%
Adult
12%
Age
11%
Pharmacokinetics
11%
Pediatric Cancer
10%
Sarcoma
10%
Diagnosis
10%
Vorinostat
10%
Event Free Survival
9%
Chemotherapeutic Agent
9%
Ewing Sarcoma
9%
Acute Lymphoblastic Leukemia
8%
Survival
8%
Crizotinib
8%
Metastatic Carcinoma
8%
Cyclophosphamide
7%
Analysis
7%
Clinical Trial
7%
Acute Myeloid Leukemia
6%
Drug
6%
Soft Tissue Sarcoma
6%
Anaplastic Large Cell Lymphoma
6%
Biological Marker
6%
Tissues
6%
Cytotoxic T-Cell
5%
Dendritic Cell
5%
Irinotecan
5%
Progression Free Survival
5%
Adverse Event
5%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
72%
Toxicity
43%
Pharmacokinetics
42%
Diseases
23%
Malignant Neoplasm
21%
Neoplasm
18%
Phase I Trials
11%
Central Nervous System Tumor
11%
Ewing Sarcoma
10%
Osteosarcoma
10%
Drug
10%
Neuroblastoma
10%
Chemotherapy
10%
Cixutumumab
10%
Crizotinib
10%
Temsirolimus
10%
Clinical Trial
10%
Pharmacodynamics
9%
Maximum Tolerated Dose
9%
Irinotecan
8%
Anaplastic Large Cell Lymphoma
8%
Leukemia
8%
Monotherapy
8%
Rhabdomyosarcoma
8%
Temozolomide
7%
Vorinostat
7%
Childhood Cancer
7%
Biological Marker
7%
Drug Development
7%
Neutropenia
7%
Sarcoma
6%
Acute Lymphoblastic Leukemia
5%
Recurrent Disease
5%
Tolerability
5%
Alisertib
5%
Nivolumab
5%
Sorafenib
5%
Adavosertib
5%
Toll Like Receptor 7
5%